Sophie Gleizes

Sophie Gleizes is a bioprocess engineer at Naobios since January 2022, specializing in the design and optimization of virus development and manufacturing processes for clinical trials, adhering to BPF guidelines. Concurrently, Sophie serves as a USP development scientist in phagotherapy at Clean Cells, focusing on laboratory establishment, bacterial culture optimization, and technology transfer documentation. Prior experience includes positions as an upstream process development scientist at Merck Life Science, where cell culture operations were optimized, and as a USP research officer at Glenmark Pharmaceuticals, specializing in monoclonal antibody process development. Sophie's background includes a significant internship at Glenmark Pharmaceuticals involving mammalian cell culture process characterization, and earlier work in establishing a stable CHO cell line producing erythropoietin. Education credentials include a Master's degree in biotechnologies from ENSTBB Bordeaux INP and preparatory studies in biology, chemistry, physics, and mathematics.